Why did BlossomHill Therapeutics (NASDAQ:BLSM) receive FDA Fast Track designation for BH-30643?

BlossomHill Therapeutics (NASDAQ:BLSM) received Fast Track designation because BH-30643 is being developed for advanced or metastatic EGFR C797S-positive NSCLC after third-generation EGFR TKI treatment.

What does Fast Track designation mean for BlossomHill Therapeutics (NASDAQ:BLSM)?

BlossomHill Therapeutics (NASDAQ:BLSM) can have more frequent FDA interactions for BH-30643, while a future application may qualify for rolling review, Accelerated Approval or Priority Review if relevant criteria are satisfied.

How is BlossomHill Therapeutics (NASDAQ:BLSM) testing BH-30643?

BlossomHill Therapeutics (NASDAQ:BLSM) is evaluating BH-30643 in SOLARA, a global Phase 1/2 first-in-human trial operating at more than 40 sites in 10 countries.

What does BlossomHill Therapeutics (NASDAQ:BLSM) BH-30643 target?

BlossomHill Therapeutics (NASDAQ:BLSM) designed BH-30643 to target EGFR mutations including C797S, T790M, classical mutations, atypical mutations and exon 20 insertions while maintaining selectivity over wild-type EGFR.

What are BlossomHill Therapeutics (NASDAQ:BLSM) other drug programs?

BlossomHill Therapeutics (NASDAQ:BLSM) is also developing BH-30236 for relapsed or refractory AML and higher-risk MDS, while BH-501284 is a preclinical pan-KRAS Switch II inhibitor.

Health

Image for illustrative purposes only. Not a real photo.

BlossomHill wins FDA Fast Track for BH-30643

Written by Liezl GambePublished Aug 18, 2026, 11:43 AM

BlossomHill Therapeutics said the FDA granted Fast Track designation to BH-30643 for advanced or metastatic EGFR C797S-positive non-small cell lung cancer.
BlossomHill shares were up 2.87% at $16.85 in premarket trading following the announcement.
The designation allows more frequent FDA interactions and may provide access to rolling review and other expedited pathways if applicable requirements are met.

BlossomHill Therapeutics (NASDAQ:BLSM) received FDA Fast Track designation for BH-30643 in adults with advanced or metastatic EGFR C797S-positive non-small cell lung cancer.

The designation covers patients previously treated with a third-generation EGFR TKI, a population for which BlossomHill says no approved oral targeted therapy currently exists.

BH-30643 is being evaluated in the global Phase 1/2 SOLARA trial at more than 40 sites across 10 countries, including C797S resistance cohorts.

Following the announcement, BlossomHill Therapeutics' share price was up 2.87% at $16.85 in premarket trading.

BH-30643 is an investigational oral, non-covalent, macrocyclic and brain-active OMNI-EGFR inhibitor designed to target several EGFR mutation categories while limiting wild-type EGFR activity.

BlossomHill is also developing BH-30236 for R/R AML and HR-MDS and preclinical BH-501284 as a pan-KRAS Switch II inhibitor for KRAS-mutant tumors.